Whether fezolinetant can treat depression and related research results

Fezolinetant is a selective neurokinin 3 receptor (NK3R) antagonist. It is currently mainly used to treat menopausal-related vasomotor symptoms (such as hot flashes and night sweats), rather than psychiatric diseases. Its mechanism of action is mainly to reduce heat symptoms caused by estrogen fluctuations by regulating the temperature regulation center of the hypothalamus. Although it targets the central nervous system, there is currently no authoritative evidence or approved indication for the use of fezonatant in the treatment of depression.

Existing research shows that some menopausal women report improvements in mood, such as reduced anxiety and improved sleep quality, after using fezonatant, but these improvements are often indirect effects caused by reductions in hot flashes. It is not because filazonatant acts directly on antidepressant mechanisms. Because hot flashes are closely related to mood disorders, the patient's subjective experience may improve when the hot flashes are relieved, but this does not mean that the drug has an antidepressant effect.

As of now, research on the relationship between filazonatant and depression remains limited. In some menopausal research data, although a trend of improvement in patients' quality of life was observed, there is no clear evidence to support its therapeutic effect on moderate or severe depression. That is to say, fezonatant has not been clinically included in any national or regional antidepressant treatment guidelines or drug recommendations.

In summary, filazonatant is not an antidepressant and is currently mainly used to relieve the symptoms of menopausal hot flashes. Although depression or sleep problems caused by hot flashes can be indirectly improved in some patients, patients with real depressive disorders should still rely on psychiatric drugs and psychotherapy, and should not use them as substitutes on their own. If the patient is in perimenopause and is accompanied by mood disorders, it is recommended to evaluate the combined treatment plan under the guidance of a professional doctor.

Reference materials:https://www.drugs.com/